{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343479","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-08-11T12:05:45+00:00","discovered_at":"2026-08-11T12:10:07.150148+00:00","generated_at":"2026-08-11T12:10:35.487597+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LB Pharma Q2 net loss $51.6M, cash $327.8M, NOVA-2 readout accelerated to H1 2027","bullets":["Q2 2026 net loss $51.6M vs $4.9M; R&D expenses $44.1M vs $2.4M.","Cash and marketable securities $327.8M at 6/30/26, plus $150M July private placement; runway beyond Q2 2029.","Pivotal Phase 3 NOVA-2 topline readout accelerated to H1 2027; pre-NDA meeting planned H2 2027.","Phase 2 bipolar depression (ILLUMINATE-1) data expected Q1 2028; MDD adjunctive trial starts early 2027.","Appointed Christopher Zergebel as SVP Clinical Operations in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343479","json":"https://secwatch.observer/filing/0001193125-26-343479.json","markdown":"https://secwatch.observer/filing/0001193125-26-343479.md","text":"https://secwatch.observer/filing/0001193125-26-343479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/0001193125-26-343479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526343479/d303033d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:10:35.487597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}